PIGU

Across TCGA pan-cancer cohorts, PIGU mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PIGU data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PIGU mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PIGU expression acts as an unfavorable survival marker, although some lineages such as LSCC and PDAC show a favorable association.

CCRCC, UCEC, and LSCC are the cancer types where PIGU mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	III,IV	0.216	0.621	.018	16	view →
UCEC	DFS	Quartile	All	0.727	1.000	.003	6	view →
LSCC	DFS	Median	All	0.804	0.612	.014	5	view →
PDAC	OS	Median	IV	0.973	0.540	.017	3	view →
GBM	OS	Median	All	0.925	0.784	.003	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PIGU–CCRCC (DFS)

Open the CCRCC breakdown →